What is the Share Price of Suven Pharmaceuticals Ltd?
- Answer Field
-
The share price of Suven Pharmaceuticals Ltd for NSE is ₹ 1133.3 and for BSE is ₹ 1125.15.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, SUVEN PHARMACEUTICALS LTD share price is currently at ₹ 1133.3, which is down by ₹ -3.09 from its previous closing. Today, the stock has fluctuated between ₹ 1126.50 and ₹ 1161.40. Over the past year, SUVEN PHARMACEUTICALS LTD has achieved a return of 72.17 %. In the last month alone, the return has been 5.87 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 275.39 |
Operating Expense | 175.97 |
Net Profit | 86.35 |
Net Profit Margin (%) | 31.35 |
Earnings Per Share (EPS) | 3.39 |
EBITDA | 130.64 |
Effective Tax Rate (%) | 24.65 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D,
Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations.
Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.
The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.
During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company.
In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.
The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.
The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21.
During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020.
As on 31 March 2020,the company has one subsidiary and one associate company under its roof.
The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.
The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..
In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.
During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.
The share price of Suven Pharmaceuticals Ltd for NSE is ₹ 1133.3 and for BSE is ₹ 1125.15.
The market cap of Suven Pharmaceuticals Ltd for NSE is ₹ 2,88,49.85 Cr. and for BSE is ₹ 2,86,42.38 Cr. as of now.
The 52 Week High and Low of Suven Pharmaceuticals Ltd for NSE is ₹ 1360.00 and ₹ 598.00 and for BSE is ₹ 1359.00 and ₹ 597.00.
You can trade in Suven Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 72.17%.
Suven Pharmaceuticals Ltd share price is for NSE ₹ 1133.3 & for BSE ₹ 1125.15 as on Apr 30 2025 03:29 PM.
The market cap of Suven Pharmaceuticals Ltd for NSE ₹ 2,88,49.85 & for BSE ₹ 2,86,42.38 as on Apr 30 2025 03:29 PM.
As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Suven Pharmaceuticals Ltd share is 102.66.
As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Suven Pharmaceuticals Ltd share is 86.66.
You can trade in Suven Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.
To buy Suven Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Suven Pharmaceuticals Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found